Sarcoidosis is a multisystem inflammatory disorder of unknown aetiology characterised by the presence of non-necrotizing granulomas. Myocardial involvement, termed cardiac sarcoidosis (CS), occurs in up to 30% of cases and can manifest with an initial presentation of high degree atrioventricular block, ventricular arrhythmias, heart failure and sudden cardiac death (SCD) (1). Investigations to aid diagnosis include echocardiogram, cardiac MRI, FDG-PET scan and endomyocardial biopsy (EMB) (2,3). Implantable cardiac defibrillator (ICD) use in CS has been widely shown to reduce risk of SCD from life-threatening arrhythmias, but factors that identify the most appropriate recipients remains unclear and is the focus of research across the world. One area of excellence spearheading new research around this topic is in Finland (4), with ongoing analysis of the MIDFIN registry – a 5-centre cardiology network first established in the 1980’s.
Author Sub-editor: Dr Pok-Tin Tang Dr Pok-Tin Tang is an ST5 cardiology registrar in the Thames Valley deanery, currently undertaking a period of out of
Author Sub-editor: Dr May Hu Dr May Hu is a cardiology trainee in the North West deanery. She graduated with First Class Honours from the University
Author Sub-editor: Dr Jhiamluka Solano Dr Jhiamluka Solano is a cardiology resident doctor (ST6) in the Yorkshire and Humber Deanery, currently undertaking a DPhil (PhD)
Author Sub-editor: Dr Joshua Rowland Dr Joshua Rowland is a cardiology registrar working in the North West Deanery. He graduated from the University of Manchester
Author Sub-editor: Dr Atmadeep Banerjee Dr Atmadeep Banerjee is an ST4 Cardiology Registrar in the Kent, Surrey and Sussex deanery. He graduated from Calcutta National
